drugset / Trial / NCT04409132

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

NCT04409132

Phase 1/2 Completed 23 enrolled Rockwell Medical Technologies, Inc.
RandomizedSequentialOpen-labelTreatment

Summary

This study will investigate the administration of Triferic AVNU intravenously by three different administration schedules compared to continuous infusion over 3 hours

Timeline

Start
2020-06-25
Primary completion
2021-04-02
Completion
2021-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Triferic Other / unclassified 0.08 mg/kg Intravenous
Subject Triferic Other / unclassified 2.25 mg Intravenous
Subject Triferic Other / unclassified 3.4 mg Intravenous
Subject Triferic Other / unclassified 6.75 mg Intravenous